Bone Biologics Corp

For the period ended Mar 31, 2024. Filed May 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Cash Flows

Three Months Ended March 31, 2024 · Three Months Ended March 31, 2023
(unaudited) · (unaudited)
Cash flows from operating activities
Net loss		$(865,970)		$(3,709,899)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		52,681		44,764
Change in fair value of warrant liability		(37,311)		562,918
Changes in operating assets and liabilities:
Advances on research and development contract services		-		267,789
Prepaid insurance		99,254		93,702
Accounts payable and accrued expenses		(137,076)		41,618
Research and development contract liabilities		-		1,349,116
Accrued legal settlement		(414,989)		-
Net cash used in operating activities		(1,303,411)		(1,349,993)
Cash flows from financing activities
Proceeds from sale of common stock units in public offering, net of offering costs		1,504,476		-
Net cash provided by financing activities		1,504,476		-
Net increase (decrease) in cash		201,065		(1,349,993)
Cash, beginning of period		3,026,569		7,538,312
Cash, end of period		$3,227,634		$6,188,319
Supplemental information
Income taxes paid	$	-	$	-
Noncash investing and financing activities
Options issued to settle accrued bonus		$77,400		-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.